Ronald M Ingram

US Patent:

8357402, Jan 22, 2013

Filed:

Jul 5, 2011

Appl. No.:

13/176174

Inventors:

Ronald T. Ingram - Encinitas CA, US
Jignesh B. Patel - Newtown PA, US
Timothy J. Pryor - Yardley PA, US

Assignee:

Integra LifeSciences Corporation - Plainsboro NJ

International Classification:

A61K 9/50
A61K 38/39
A61K 47/48

US Classification:

424499, 514 172

Abstract:

This invention relates to a flowable collagen/glycosaminoglycan (GAG) material including particles of collagen/GAG matrix that, when hydrated, can be effectively delivered to wounds having varying depths and geometries. The flowable collagen/GAG matrix allows a more intimate contact between the wound matrix and the wound bed, and provides a structural framework that serves as a scaffold for cell ingrowth.

US Patent:

7993679, Aug 9, 2011

Filed:

Sep 19, 2008

Appl. No.:

12/233936

Inventors:

Ronald T. Ingram - Encinitas CA, US
Jignesh B. Patel - Newtown PA, US
Timothy J. Pryor - Yardley PA, US

Assignee:

Integra LifeSciences Corporation - Plainsboro NJ

International Classification:

A61K 9/50
A61K 38/39
A61K 47/48

US Classification:

424499, 514 172

Abstract:

This invention relates to a flowable collagen/glycosaminoglycan (GAG) material including particles of collagen/GAG matrix that, when hydrated, can be effectively delivered to wounds having varying depths and geometries. The flowable collagen/GAG matrix allows a more intimate contact between the wound matrix and the wound bed, and provides a structural framework that serves as a scaffold for cell ingrowth.

US Patent:

57927456, Aug 11, 1998

Filed:

Apr 12, 1995

Appl. No.:

8/421697

Inventors:

Soan Cheng - San Diego CA
Ronald Ingram - Oceanside CA
Daniel Mullen - San Diego CA
Juerg F. Tschopp - San Diego CA

Assignee:

La Jolla Cancer Research Center - La Jolla CA

International Classification:

A61K 3808
A61K 3812
C07K 706
C07K 754

US Classification:

514 11

Abstract:

The present invention provides Arg-Gly-Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to alter. alpha. sub. v. beta. sub. 3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.

US Patent:

57599963, Jun 2, 1998

Filed:

Apr 12, 1995

Appl. No.:

8/421702

Inventors:

Soan Cheng - San Diego CA
Ronald Ingram - Oceanside CA
Daniel Mullen - San Diego CA
Juerg F. Tschopp - San Diego CA

Assignee:

La Jolla Cancer Research Center - La Jolla CA

International Classification:

A61K 3808
A61K 3810
A61K 3812
A61K 3816

US Classification:

514 11

Abstract:

The present invention provides Arg-Gly-Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to alter. alpha. sub. v. beta. sub. 3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.

US Patent:

58078193, Sep 15, 1998

Filed:

Apr 12, 1995

Appl. No.:

8/421698

Inventors:

Soan Cheng - San Diego CA
Ronald Ingram - Oceanside CA
Daniel Mullen - San Diego CA
Juerg F. Tschopp - San Diego CA

Assignee:

La Jolla Cancer Research Center - La Jolla CA

International Classification:

A61K 3808
A61K 3810
A61K 3812
A61K 3816

US Classification:

514 11

Abstract:

The present invention provides Arg--Gly--Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg--Gly--Asp peptides to alter. alpha. sub. V. beta. sub. 3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.

US Patent:

58498656, Dec 15, 1998

Filed:

Apr 12, 1995

Appl. No.:

8/421695

Inventors:

Soan Cheng - San Diego CA
Ronald Ingram - Oceanside CA
Daniel Mullen - San Diego CA
Juerg F. Tschopp - San Diego CA

Assignee:

La Jolla Cancer Research Foundation - San Diego CA

International Classification:

A61K 3808
C07K 706
C07K 707
C07K 754

US Classification:

530317

Abstract:

The present invention provides Arg-Gly-Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to alter. alpha. sub. v. beta. sub. 3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.

US Patent:

57734127, Jun 30, 1998

Filed:

Apr 12, 1995

Appl. No.:

8/421696

Inventors:

Soan Cheng - San Diego CA
Ronald Ingram - Oceanside CA
Daniel Mullen - San Diego CA
Juerg F. Tschopp - San Diego CA

Assignee:

La Jolla Cancer Research Center - La Jolla CA

International Classification:

A61K 3808
A61K 3810
A61K 3812
A61K 3816

US Classification:

514 11

Abstract:

The present invention provides Arg--Gly--Asp peptides that can alter the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg--Gly--Asp peptides to alter. alpha. sub. v. beta. sub. 3 integrin receptor-mediated binding of a cell such as an osteoclast, endothelial cell or smooth muscle cell to a matrix. The invention further provides methods for ameliorating the severity of a pathology characterized, in part, by an undesirable level of bone resorption, angiogenesis or restenosis in a subject.

US Patent:

57705658, Jun 23, 1998

Filed:

Sep 8, 1994

Appl. No.:

8/303052

Inventors:

Soan Cheng - San Diego CA
Ronald Ingram - Oceanside CA
Daniel Mullen - San Diego CA
Juerg Tschopp - San Diego CA

Assignee:

La Jolla Cancer Research Center - La Jolla CA

International Classification:

A61K 3808
A61K 3810
C07K 706
C07K 708

US Classification:

514 11

Abstract:

The present invention provides Arg-Gly-Asp peptides that can reduce or inhibit the binding of osteoclasts to a matrix such as bone or can selectively alter integrin receptor binding. The invention also provides methods of using the Arg-Gly-Asp peptides to reduce or inhibit osteoclast binding to a matrix, to reduce or inhibit bone resorption in a subject and to alter. alpha. sub. V. beta. sub. 3 binding.